Detalles de la búsqueda
1.
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Lancet
; 399(10319): 36-49, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34883053
2.
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Clin Exp Immunol
; 211(3): 280-287, 2023 03 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-36729167
3.
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Lancet
; 398(10304): 981-990, 2021 09 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34480858
4.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Lancet
; 397(10282): 1351-1362, 2021 04 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33798499
5.
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Lancet
; 398(10303): 856-869, 2021 09 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34370971
6.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Lancet
; 396(10267): 1979-1993, 2021 12 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33220855
7.
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Lancet
; 397(10277): 881-891, 2021 03 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33617777
8.
Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination.
J Infect Dis
; 223(7): 1171-1182, 2021 04 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31821493
9.
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Lancet
; 396(10249): 467-478, 2020 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32702298
10.
No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccine.
J Allergy Clin Immunol
; 137(6): 1772-1779.e11, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26825000
11.
Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
JAMA
; 315(15): 1610-23, 2016 Apr 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-27092831
12.
BCR repertoire sequencing: different patterns of B-cell activation after two Meningococcal vaccines.
Immunol Cell Biol
; 93(10): 885-95, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25976772
13.
The effect of chronic cytomegalovirus infection on pneumococcal vaccine responses.
J Infect Dis
; 209(10): 1635-41, 2014 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24302755
14.
Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells.
J Infect Dis
; 205(9): 1408-16, 2012 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22457293
15.
Regulatory T cell profiles in patients with N-methyl-á´ -aspartate receptor-antibody encephalitis.
Encephalitis
; 3(1): 15-23, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37469716
16.
Memory-like innate response to booster vaccination with MF-59 adjuvanted influenza vaccine in children.
NPJ Vaccines
; 8(1): 100, 2023 Jul 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-37443176
17.
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
Nat Med
; 29(1): 147-157, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36228659
18.
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.
J Infect
; 87(3): 230-241, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37331429
19.
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
J Infect
; 86(6): 574-583, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37028454
20.
Memory B Cell Activation Induced by Pertussis Booster Vaccination in Four Age Groups of Three Countries.
Front Immunol
; 13: 864674, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35677044